Enhanced Vector Bioprocessing Technologies for Cell and Gene Therapies

Lead Participant: SYNPROMICS LTD

Abstract

Evolving therapeutic approaches of cell and gene therapy are harnessing the power of viruses in order to

modify genomes of cells to produce a therapeutic effect. Such therapies are starting to show efficacy in the

clinic, but one of the key challenges to their widespread use is the ability to make large quantities of virus at a

low cost. This project seeks to address this challenge by creating new methods of producing large quantities of

virus at a low cost. It brings together Synpromics, a synthetic biology company based in Edinburgh, and the Cell

Therapy Catapult, one of the UK’s network of Catapult centres focused on developing and growing a cell and

gene therapy industry in the UK.

Lead Participant

Project Cost

Grant Offer

SYNPROMICS LTD £1,387,753 £ 971,427
 

Participant

CELL THERAPY CATAPULT LIMITED £606,297 £ 606,297
THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST

Publications

10 25 50